Morita Pharmaceutical resolved to make executive changes at the Board of Directors meeting held on June 25, 2026, announcing new appointments and role changes. This includes changes in the representative director and directors, as well as the appointment of a candidate for auditing role.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4534","jir_company_name":"Morita Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-05-15","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/05\/4534-20260515-02.pdf","jir_short_summary":"Morita Pharmaceutical resolved to make executive changes at the Board of Directors meeting held on June 25, 2026, announcing new appointments and role changes. This includes changes in the representative director and directors, as well as the appointment of a candidate for auditing role.","jir_summary":"### Overview of Executive Changes\nMorita Pharmaceutical resolved to implement executive changes at the Board of Directors meeting held on June 25, 2026, announcing role changes for the representative director and the appointment of new executives. Junichi Sakaki and Motoo Mitsuishi will continue to serve as representative directors, with Kenji Morita scheduled to be appointed as an officer overseeing Business Development. Role changes for directors and the appointment of candidates for auditors were also announced, aiming to strengthen management.\n\n### Future Outlook and Impact\nThese executive personnel changes are aimed at advancing Morita Pharmaceutical\u2019s business strategy and strengthening governance, and will be officially confirmed after approval at the shareholders' meeting on June 25, 2026. The new structure is expected to enhance efficiency in R&D and business development, as well as improve management stability. For investors, the refreshing of management is regarded as part of the company's medium- to long-term growth strategy.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#MoritaPharmaceutical, #ExecutiveChanges, #JapanStocks","jir_key_figures":"Representative director role change: Junichi Sakaki and Motoo Mitsuishi\nNew officer candidate: Kenji Morita (overseeing Business Development)\nAuditor candidate: Reiko Nakano (Full-time auditor)","jir_meta_title":"\u3010Morita Pharmaceutical\u3011Announcement of Executive Changes | June 25, 2026","jir_meta_description":"Morita Pharmaceutical resolved to implement executive changes on June 25, 2026, announcing new appointments and role changes. This article explains the personnel changes aimed at strengthening management and promoting business development.","jir_og_title":"\u3010Morita Pharmaceutical\u3011Executive Change Announcement | June 25, 2026","jir_og_description":"Morita Pharmaceutical resolved to implement executive changes on June 25, 2026. The appointment of new officers and role changes aim to strengthen management and promote business development.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":9404,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-52171","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n